Frequently Asked Questions:
What is regenerative medicine?
Regenerative medicine is the exciting cutting-edge “medicine of the future” which holds the hope & the promise of efficacy which revolves around the ability of human tissue to be repaired, replaced, and healed (regenerated) once human tissues and organs are damaged or diseased. Regenerative therapies aid and supplement the natural healing mechanisms of the body. These therapies often employ the activation of stem cells to stimulate renewal of tissue damaged by injury, disease, or age. The rapid expansion of scientific knowledge offers great promise for continuing advances in this field of medicine which holds vast potential to improve the quality of human life.
What are stem cells?
Stem cells are the basic building blocks of life. They are unspecialized cells that can produce more stem cells through mitosis or differentiate into specialized cells that carry out specific functions in the body. Stem cells are found throughout the body’s tissues, organs, and systems although usually in small quantities in adults.
What are hematopoietic stem cells?
Hematopoietic stem cells (HSCs) can give rise to all types of blood cells including red blood cells, white blood cells, and platelets. They are particularly useful in the treatment of blood-related diseases and conditions.
What are mesenchymal stem cells?
Mesenchymal Stem Cells (MSCs) are multipotent stromal cells that are non-blood forming stem cells and can differentiate into a variety of cell types including muscle, bone, cartilage, and fat cells.
When introduced into a patient’s body, MSCs can repair or replace damaged or degenerating tissue by communicating with the surrounding cells thus causing a cellular cascade of healing (paracrine signaling).
Historically, the term MSC was coined in the late 80’s by the biomedical research authority, Dr. Arnold Caplan of Case Western Reserve. The acronym has recently been redefined by Caplan to “Medicinal Signaling Cell” since these cells secrete powerful bioactive molecules involved in cellular signaling and regeneration. Caplan now describes MSCs as a “multisite-regulatory dispensary” (Natural Drug Store).
The production of MSCs in the human body, can be precipitated by bioactive placental tissues containing Growth Factors, Cytokins and other powerful bioactive agents which trigger cell signaling.
The remarkable ability of MSCs make them irreplaceable in medical treatments.
What are accessible sources of stem cells?
Stem cells can be extracted from various parts of the body. They have been extracted from bone marrow and adipose tissue for a few decades. More recently, birth tissues from live births, including umbilical cord blood, cord tissue, with Wharton’s Jelly, and amniotic membrane tissue, have been found to be a rich source of both HSCs and MSCs and in addition, precipitate target tissue production of MSCs through paracrine signaling. Growth Factors, Cytokins, Exosomes & micro-RNA from birth tissues give rise to Stem cells in this way. These cells, as well as MSCs contained in Wharton’s Jelly tend to be more fit than stem cells obtained from adult stem cells.
Wharton’s jelly is a gelatinous substance found in the umbilical cord which is rich in stem cells. Studies have shown that mesenchymal stem cells (MSCs) have low immunogenicity. Human umbilical cord Wharton’s jelly provides a new source for MSCs that are highly proliferative and have multi-differentiation potential. Wharton’s Jelly Cells (WJCs) express MSC markers but low levels of human leukocyte antigen (HLA)-ABC and no HLA-DR. WJCs have low functional immunogenicity and therefore recipient rejection has not been documented.
Advanced Regenerative Medicine
Advanced Regenerative Medicine involves the use of regenerative biomolecules, tissue engineering and stem cells to treat diseased or injured tissues.
What are potential uses of stem cells?
Advanced regenerative medicine has been used for decades to treat blood-related diseases through bone marrow transplants. In recent years, stem cells have been increasingly used more widely to treat a variety of diseases and conditions including diabetes, rheumatoid arthritis, Parkinson’s disease, ALS, would healing, heart disease, autoimmune disorders, and the list of possibilities is growing at an amazing rate.
What is an allograft?
An allograft is tissue that is transplanted from one person to another through injection or surgery.
Walther, Mary Margaret (2009). “Chapter 39. Cord Blood Hematopoietic Cell Transplantation”. In Appelbaum, Frederick R.; Forman, Stephen J.; Negrin, Robert S.; Blume, Karl G. Thomas’ hematopoietic cell transplantation stem cell transplantation (4th ed.). Oxford: Wiley-Blackwell.
Mao, Angelo S and Mooney, David J, “Regenerative medicine: Current therapies and future directions.” Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14452-9.
Buckler L. “Opportunities in regenerative medicine.” Bioprocess Int 2011 (March), 14-18.
Haller M J; et al. (2008). “Autologous umbilical cord blood infusion for type 1 diabetes”. Exp. Hematol. 36 (6): 710–715. PMC 2444031 Freely accessible.
El Omar R; Beroud J; Stoltz JF; Menu P; Velot E, Decot V. ”Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies?” Tissue Eng Part B Rev. 2014 Oct;20(5):523-44. doi: 10.1089/ten.TEB.2013.0664. Epub 2014 Apr 22.
Bailey AM; Mendicino, M; Au P. “An FDA perspective on preclinical development of cell-based regenerative medicine products.” Nature Biotechnology 32, 721–723 (August 2014)
Caseiro, AR; Pereira, T; Ivanova, G; Luís, AL; Maurício, AC (2016). “Neuromuscular Regeneration: Perspective on the Application of Mesenchymal Stem Cells and Their Secretion Products.”. Stem cells international. 2016: 9756973. PMC 4736584 Freely accessible.
Roura S, Pujal JM, Gálvez-Montón C, Bayes-Genis A (2015). “Impact of umbilical cord blood-derived mesenchymal stem cells on cardiovascular research”. BioMed Research International. 2015: 975302. PMC 4377460 Freely accessible.
Li, T; Xia, M; Gao, Y; Chen, Y; Xu, Y (2015). “Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy.”. Expert opinion on biological therapy. 15 (9): 1293–306.
Murphy MB; Moncivais K; Caplan AI. “Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine.” Exp Mol Med. 2013 Nov 15;45:e54.
Zhang Y; Chai C; Jiang XS; Teoh SH; Leong KW. “Co-culture of umbilical cord blood CD34+ cells with human mesenchymal stem cells.” Tissue Eng. 2006 Aug;12(8):2161-70.
Cosgrove BD; Gilbert PM; Porpiglia E; Mourkioti F; Lee SP; Corbel SY; Llewellyn ME; Delp SL; Blau HM. “Rejuvenation of the muscle stem cell population restores strength to injured aged muscles.” Nat Med. 2014 Mar;20(3):255-64.